🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Leeds
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Leeds

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2850 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 23 Sep 2026, 03:15 UTC
2850
Studies in scope
industry-sponsored, all four open statuses
1383
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2005 Manchester 672 Birmingham 470 Glasgow 437 Cambridge 417
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca27 Janssen Research & Development, LLC14 BeOne Medicines9 Bristol-Myers Squibb9 AbbVie9
Site city
London2005 Manchester672 Birmingham470 Glasgow437 Cambridge417
All 425 cities
Target enrolment
to
317 of 2850 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Active, closed
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
NCT05444257Cystic Fibrosis
Vertex Pharmaceuticals Incorporated
Phase 3
822
Birmingham, Bristol, Cambridge, Edinburgh, Exeter, Glasgow, Leeds, Liverpool
2022-11-08
Active, closed
A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH
NCT05389449Paroxysmal Nocturnal Hemoglobinuria
Alexion Pharmaceuticals, Inc.
Phase 3
80
Airdrie, Leeds, London
2022-10-28
Recruiting
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05253651Colorectal Neoplasms
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
400
Newcastle upon Tyne, Glasgow, Sutton, Bristol, Cambridge, Leeds, London, Manchester
2022-10-24
Recruiting
Rocket Study: A Study to Characterize Biomarkers and Disease Progression in Participants With Pelizaeus-Merzbacher Disease
NCT05659901Pelizaeus-Merzbacher Disease
Ionis Pharmaceuticals, Inc.
Observational
32
Leeds
2022-10-03
Active, closed
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
NCT05409066Follicular Lymphoma (FL)
Genmab
Phase 3
549
Plymouth, Glasgow, London, Oxford, Leeds, Birmingham, Colchester, Liverpool
2022-09-20
Active, closed
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT05531565Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Biogen
Phase 2/3
450
London, Manchester, Birmingham, Leeds
2022-09-13
Recruiting
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
NCT05489705Obstructive Hypertrophic Cardiomyopathy
Bristol-Myers Squibb
Observational
1,700
London, Manchester, Liverpool, Birmingham, Leeds, Cardiff
2022-08-16
Active, closed
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
NCT05524883Duchenne Muscular Dystrophy (DMD)
Dyne Therapeutics
Phase 1/2
86
Liverpool, Newcastle upon Tyne, Leeds, Bristol, London
2022-08-12
Active, closed
Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
NCT05349214Sjogren Syndrome
Novartis Pharmaceuticals
Phase 3
506
Doncaster, Leeds, Liverpool, Newcastle upon Tyne, Swindon
2022-08-04
Active, closed
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
NCT05489237Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases
IDRX, Inc., a wholly owned subsidiary of GSK, LLC
Phase 1
276
Leeds, London
2022-08-03
Active, closed
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
NCT05133531Paroxysmal Nocturnal Hemoglobinuria
Regeneron Pharmaceuticals
Phase 3
202
Leeds
2022-08-01
Active, closed
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286Triple Negative Breast Cancer, PD-L1 Positive
Gilead Sciences
Phase 3
443
Edinburgh, Glasgow, Leeds, London, Nottingham
2022-07-25
Active, closed
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299Triple Negative Breast Cancer, PD-L1 Negative
Gilead Sciences
Phase 3
623
Leeds, London
2022-07-20
Active, closed
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
NCT05352672Melanoma
Regeneron Pharmaceuticals
Phase 3
1,546
Exeter, Cottingham, Leeds, Guildford
2022-07-14
Active, closed
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
NCT05338970Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
Daiichi Sankyo
Phase 3
586
Birmingham, Glasgow, Leeds, Leicester, London, Manchester, Wolverhampton
2022-07-08
Recruiting
International Wilson's Disease Patient Registry (iWilson Registry)
NCT05239858Wilson's Disease
Orphalan
Observational
500
Leeds, London
2022-06-29
Recruiting
First in Human Study of T3P-Y058-739 (T3P)
NCT05120596Advanced Solid Tumor
T3 Pharmaceuticals AG
Phase 1/2
100
Glasgow, Leeds, London, Southampton
2022-04-26
Recruiting
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
NCT05131022Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL)
Nurix Therapeutics, Inc.
Phase 1
572
Manchester, Glasgow, Leeds, Liverpool, London, Oxford, Plymouth, Southampton
2022-04-13
Recruiting
Zimmer® Natural Nail® (ZNN) Bactiguard Tibia Post-Market Clinical Follow-up Study
NCT05022485Tibial Fractures, Fracture Infection
Zimmer Biomet
Observational
500
Edinburgh, Leeds, London
2022-04-11
Recruiting
Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Male and Female Subjects and Safety, Tolerability, Pharmacokinetics, and Pilot Efficacy Biomarkers in Subjects With Cold Agglutinin Disease
NCT05318534First in Man Study to Evaluate Initial Safety
Gliknik Inc.
Phase 1
70
Leeds
2022-04-08
Active, closed
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
NCT05270668Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
154
London, Leeds
2022-03-29
Recruiting
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
NCT04895436Chronic Lymphocytic Leukemia (CLL)
AbbVie
Phase 2
75
Blackpool, Norwich, Leeds
2022-03-28
Active, closed
LEVANTIS-0093A: GAGomes for Multi-Cancer Early Detection in High-Risk Adults (LEV93A)
NCT05295017Cancer
Elypta
Observational
1,235
Leeds
2022-03-14
Active, closed
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
NCT05100862Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
BeOne Medicines
Phase 3
799
Glasgow, Greater Manchester, Huddersfield, Inverness, Leeds, London, Plymouth, Southampton
2022-03-10
Active, closed
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
NCT05211895Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
791
Birmingham, Brighton, Cardiff, Cheltenham, Edinburgh, High Heaton/Newcastle Upon Tyn, Leeds, London
2022-02-18
Active, closed
Clinical Impact of the IBox As an Early Intervention TooL
NCT05112315Kidney Diseases, Kidney Disease, Chronic, Kidney Transplant Rejection, Kidney Transplant; Complications
Predict4Health
Not applicable
507
Birmingham, Leeds, London, Oxford
2022-02-18
Active, closed
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
AbbVie
Phase 3
735
Aylesbury, London, Gloucester, Southampton, Oxford, Leeds, Bradford, Bristol
2022-01-13
Recruiting
A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis
NCT05037760Myelofibrosis
Takeda
Phase 2
135
Boston, Leeds, London
2021-12-16
Active, closed
Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)
NCT05002777Warm Autoimmune Hemolytic Anemia (wAIHA)
Sanofi
Phase 2
22
Leeds, London
2021-12-07
Active, closed
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
NCT05152147Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
Jazz Pharmaceuticals
Phase 3
920
Bristol, Edinburgh, Leeds, London, Peterborough, Sheffield
2021-12-02
Active, closed
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
NCT05091567Small-Cell Lung Cancer
Hoffmann-La Roche
Phase 3
660
Blackpool, GB Manchester, Hull, Leeds, Leicester, London
2021-11-18
Active, closed
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT05089734Non-Small Cell Lung Cancer
Gilead Sciences
Phase 3
603
Birmingham, Colchester, Glasgow, Leeds, Leicester, London, Manchester
2021-11-17
Recruiting
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
NCT04996875Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN), Mast Cell Leukemia (MCL), Aggressive Systemic Mastocytosis (ASM)
Cogent Biosciences, Inc.
Phase 2
140
Leeds, London
2021-11-09
Recruiting
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
NCT05065216Acute Stroke, Ischemic Stroke, Stroke
DiaMedica Therapeutics Inc
Phase 2/3
728
Exeter, Newcastle upon Tyne, Cambridge, London, Stoke-on-Trent, Kirkcaldy, Leeds, Middlesbrough
2021-11-07
Active, closed
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus
NCT04963296Systemic Lupus Erythematosus
Hoffmann-La Roche
Phase 3
303
Cambridge, Leeds, London, Manchester
2021-10-26
Active, closed
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT04965493Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Loxo Oncology, Inc.
Phase 3
600
Birmingham, Leeds, Leicester, London, Oxford, Plymouth
2021-09-20
Recruiting
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
BeOne Medicines
Phase 1/2
645
Edinburgh, Leeds, Newcastle upon Tyne, Newmarket, Norwich, Nottingham, Plymouth
2021-09-13
Active, closed
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
NCT04929210Arthritis, Psoriatic
Janssen Research & Development, LLC
Phase 4
411
Barnet, Bradford, Coventry, Leeds, Manchester, Newcastle, Stoke-on-Trent
2021-08-30
Active, closed
A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice
NCT05049798Arthritis, Psoriatic
Janssen Pharmaceutica N.V., Belgium
Observational
1,314
Aberdeen, Abergavenny, Airdrie, Barnet, Bath, Glasgow, Hull, Leeds
2021-08-25
Active, closed
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
NCT04923893Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
743
Birmingham, Bristol, Leeds, London, Manchester, Surrey
2021-08-19
Active, closed
Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT04747613Paroxysmal Nocturnal Hemoglobinuria
Novartis Pharmaceuticals
Phase 3
208
Leeds, London
2021-07-27
Active, closed
Effectiveness of the EMPOWER™ Modular Pacing System and EMBLEM™ Subcutaneous ICD to Communicate Antitachycardia Pacing
NCT04798768Tachycardia, Ventricular, Arrhythmia, Ventricular
Boston Scientific Corporation
Not applicable
297
Leeds, Liverpool, Manchester, Southampton
2021-07-20
Recruiting
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
NCT04969835Salivary Gland Tumor, Urothelial Carcinoma, Ovarian Carcinoma, Breast Cancer
Avacta Life Sciences Ltd
Phase 1
158
Glasgow, Leeds, London, Manchester, Newcastle upon Tyne, Sheffield
2021-07-16
Active, closed
Evaluation of TAVR Using the NAVITOR Valve in a Global Investigation
NCT04788888Symptomatic Severe Aortic Stenosis
Abbott Medical Devices
Not applicable
434
Swansea, Belfast, Leeds, London
2021-07-13
Active, closed
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
NCT04915755Neoplasms, Breast
GlaxoSmithKline
Phase 3
40
Bath, Brighton, Cardiff, Coventry, Edinburgh, Leeds, London, Maidstone
2021-06-28
Active, closed
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
NCT04793958Advanced Colorectal Cancer, Metastatic Colorectal Cancer
Mirati Therapeutics Inc.
Phase 3
461
Aberdeen, Birmingham, Cambridge, Dorset, Glasgow, Kent, Leeds, London
2021-06-24
Active, closed
Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus
NCT04877691Systemic Lupus Erythematosus
AstraZeneca
Phase 3
367
Doncaster, Leeds, London
2021-06-08
Active, closed
The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy (#HOPE4LIVER EU/UK)
NCT04573881Liver Neoplasms, Hepatocellular Carcinoma, Liver Metastases
HistoSonics, Inc.
Not applicable
24
Leeds, Newcastle
2021-06-04
Recruiting
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
NCT04811560Acute Leukemia
Janssen Research & Development, LLC
Phase 1/2
420
Cardiff, Leeds, Liverpool, London, Manchester, Oxfordshire, Plymouth
2021-05-19
Active, closed
SMall Annuli Randomized To Evolut™ or SAPIEN™ Trial
NCT04722250Symptomatic Aortic Stenosis, Aortic Valve Stenosis, Aortic Valve Replacement
Medtronic Cardiovascular
Not applicable
1,103
Edinburgh, Leeds
2021-04-02
Recruiting
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
NCT04502394Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
Kartos Therapeutics, Inc.
Phase 1/2
84
Leeds, London, Southampton
2021-02-23
Active, closed
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04408638Diffuse Large B-cell Lymphoma
Hoffmann-La Roche
Phase 3
270
Glasgow, Leeds, London, Manchester, Nottingham
2021-02-23
Active, closed
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
NCT04711252ER-Positive HER2-Negative Breast Cancer
AstraZeneca
Phase 3
1,370
Cambridge, Colchester, Leeds, Nottingham, Surrey
2021-01-28
Active, closed
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
NCT04534205Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
BioNTech SE
Phase 2/3
358
Aberdeen, Belfast, Birmingham, Cambridge, Cardiff, Glasgow, Leeds, Liverpool
2021-01-07
Active, closed
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
NCT04663308Primary Sclerosing Cholangitis
Mirum Pharmaceuticals, Inc.
Phase 2
182
London, Oxford, Belfast, Birmingham, Cambridge, Edinburgh, Leeds, Newcastle upon Tyne
2020-12-18
Active, closed
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
NCT04640623Urinary Bladder Neoplasms
Janssen Research & Development, LLC
Phase 2
220
Glasgow, Leeds
2020-12-18
Active, closed
Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
NCT04794101X-Linked Retinitis Pigmentosa
Janssen Research & Development, LLC
Phase 3
97
Edinburgh, Glasgow, Leeds, London
2020-12-04
Active, closed
A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease
NCT04540497IgG4 Related Disease
Amgen
Phase 3
135
Leeds, London, Newcastle, Oxford
2020-12-04
Active, closed
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
NCT04622319HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
Daiichi Sankyo
Phase 3
1,600
Peterborough, Maidstone, Manchester, Metropolitan Borough of Wirral, Nottingham, Bath, Taunton, Leeds
2020-12-04
Active, closed
A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors
NCT04434092Paroxysmal Nocturnal Hemoglobinuria
Hoffmann-La Roche
Phase 3
210
Leeds, London
2020-10-08
Active, closed
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
NCT04494425Advanced or Metastatic Breast Cancer
AstraZeneca
Phase 3
866
Cambridge, Cardiff, Edinburgh, Guildford, Leeds, London, Manchester, Northwood
2020-07-24
Active, closed
A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)
NCT03992430Muscular Dystrophy, Duchenne
Sarepta Therapeutics, Inc.
Phase 3
160
Leeds, Birmingham, London
2020-07-13
Active, closed
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
NCT04380636Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC
Phase 3
870
Sheffield, London, London-Camden, Southampton, Leeds, Manchester
2020-07-06
Active, closed
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
NCT04478279Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer
Sapience Therapeutics
Phase 1/2
125
Edinburgh, Glasgow, Leeds, London
2020-07-01
Active, closed
Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies
NCT04277637Mature B-Cell Malignancies
BeOne Medicines
Phase 1
437
Leeds
2020-03-24
Active, closed
A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib
NCT04170283B-cell Malignancies
BeOne Medicines
Phase 3
955
Aberdeen, Birmingham, Bournemouth, Canterbury, Glasgow, Greater Manchester, Headington, Leeds
2020-01-16
Recruiting
A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis
NCT03969329Secondary Hyperparathyroidism
Amgen
Phase 3
24
Glasgow, Leeds, London, Southampton
2019-12-20
Active, closed
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
NCT04180371Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer
BicycleTx Limited
Phase 1/2
288
London, Manchester, Cambridge, Leeds, Newcastle upon Tyne
2019-11-07
Active, closed
SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)
NCT04079166Malignant Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV
Scancell Ltd
Phase 2
173
Cambridge, Cardiff, Leeds, London, Manchester, Northwood, Nottingham, Oxford
2019-08-19
Active, closed
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia
NCT04119050Warm Autoimmune Hemolytic Anemia
Janssen Research & Development, LLC
Phase 2/3
118
Leeds, Liverpool, London, Oxford, Plymouth, Southampton
2019-08-15
Recruiting
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
NCT04064060Myelodysplastic Syndromes (MDS), Beta-thalassemia, Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
Celgene
Phase 3
665
Aberdeen, Leeds, London, Oxford, Sutton in Ashfield
2019-08-12
Recruiting
Expanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk
NCT04029363Mitral Regurgitation
HighLife SAS
Not applicable
120
Belfast, Brighton, Edinburgh, Leeds, Leicester, London, Oxford
2019-05-28
Active, closed
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
NCT03709680Ewing Sarcoma, Solid Tumors, Rhabdoid Tumor, Rhabdomyosarcoma
Pfizer
Phase 2
128
Newcastle upon Tyne, Glasgow, Leeds, London
2019-05-24
Recruiting
Long-Term Real-World Outcomes Study on Patients Implanted With a Neurostimulator
NCT03876054Chronic Pain
Abbott Medical Devices
Observational
2,000
Norwich, Liverpool, Bristol, Leeds
2019-03-13
Active, closed
Durvalumab and Tremelimumab for Pediatric Malignancies
NCT03837899Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies
AstraZeneca
Phase 1/2
50
Leeds, London, Sutton
2019-03-07
Active, closed
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
NCT03833154Carcinoma, Non-Small-Cell Lung
AstraZeneca
Phase 3
724
Birmingham, Leeds, London, Manchester
2019-03-06
Active, closed
A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
NCT03673501Gastrointestinal Stromal Tumors
Deciphera Pharmaceuticals, LLC
Phase 3
453
Glasgow, Leeds, London, Sheffield
2019-02-08
Active, closed
Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.
NCT03616587ER+ HER2- Advanced Breast Cancer
AstraZeneca
Phase 1
396
Cambridge, Leeds, London, Manchester, Sutton
2018-10-11
Recruiting
A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)
NCT02991469Juvenile Idiopathic Arthritis
Sanofi
Phase 2
51
London, Leeds, Liverpool
2018-08-09
Active, closed
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
NCT03568318Atopic Dermatitis
AbbVie
Phase 3
1,533
London, Oxford, Dundee, Glasgow, Leeds
2018-08-09
Recruiting
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
NCT03435796Neoplasms
Celgene
Phase 2/3
1,541
Leeds, London, Manchester Withington, Shirley Southampton
2018-07-19
Active, closed
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
NCT03504397Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Global Development, Inc.
Phase 3
565
Aberdeen, London, Sutton, Cambridge, Coventry, Dundee, Leeds, Manchester
2018-06-21
Active, closed
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
NCT03522246Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed
pharmaand GmbH
Phase 3
1,097
Canterbury, Cliftonville, Brighton, Bristol, Cambridge, Edinburgh, Lancaster, Leeds
2018-05-14
Active, closed
A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT03462719Leukemia, Lymphocytic, Chronic, B-Cell
Janssen Research & Development, LLC
Phase 3
211
Birmingham, Cambridge, Charterhouse Square, Glasgow, Leeds, Plymouth, Romford, Sheffield
2018-04-17
Active, closed
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
NCT03363373Neuroblastoma
Y-mAbs Therapeutics
Phase 2
122
Glasgow, Leeds, Southampton
2018-04-03
Active, closed
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
NCT03423628Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme, Brain Neoplasms, Malignant, Leptomeningeal Disease (LMD)
AstraZeneca
Phase 1
159
Cambridge, Glasgow, Leeds
2018-04-02
Active, closed
A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
NCT03328273Chronic Lymphocytic Leukemia
Acerta Pharma BV
Phase 1
12
Birmingham, Bournemouth, Cardiff, Leeds, London, Nottingham, Oxford, Southampton
2018-01-31
Recruiting
The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR
NCT03142152Functional Mitral Regurgitation, Heart Failure, Mitral Valve Insufficiency, Heart Diseases
Cardiac Dimensions, Inc.
Not applicable
300
Leeds
2018-01-01
Active, closed
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
NCT03336333Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
BeiGene
Phase 3
590
Birmingham, Bournemouth, Cambridge, Canterbury, Greater Manchester, Leeds, London, Maidstone
2017-10-31
Active, closed
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
NCT03767348Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma
Replimune, Inc.
Phase 2
340
Leeds, Oxford, Glasgow, Bebington, London, Southampton
2017-09-20
Active, closed
ATTUNE® Revision- Complex Primary in Total Knee Arthroplasty Population
NCT03153449Primary Knee Arthroplasty
DePuy Orthopaedics
Not applicable
400
Basingstoke, Kirkcaldy, Leeds, Middlesbrough, Oswestry, Oxford, Wigan
2017-09-19
Active, closed
ATTUNE Revision System in the Revision Total Knee Arthroplasty Population
NCT03153475Revision Total Knee Arthroplasty
DePuy Orthopaedics
Not applicable
400
Basingstoke, Kirkcaldy, Leeds, North Yorks, Oswestry, Oxford, Wigan
2017-05-30
Active, closed
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
NCT03229200Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Leukemia, B-cell, Graft Vs Host Disease
Pharmacyclics Switzerland GmbH
Phase 4
297
Cardiff, Leeds, London, Manchester
2017-05-22
Active, closed
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
NCT02773030Multiple Myeloma
Celgene
Phase 1/2
466
Birmingham, Leeds, Oxford, Sutton
2016-10-14
Active, closed
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
NCT02811861Renal Cell Carcinoma
Eisai Inc.
Phase 3
1,069
Bournemouth, Cardiff, Edinburgh, Glasgow, Leeds, London, Manchester
2016-10-13
Active, closed
A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
NCT02717611Chronic Lymphocytic Leukemia
Acerta Pharma BV
Phase 2
60
Bournemouth, Leeds, Manchester
2016-03-08
Active, closed
Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
NCT02598661Myelodysplastic Syndromes
Geron Corporation
Phase 2/3
289
Leeds, Nottingham, Southampton, Aberdeen
2016-01-12
Active, closed
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
NCT02516241Urothelial Cancer
AstraZeneca
Phase 3
1,126
Cambridge, Cardiff, Glasgow, Leeds, London, Manchester, Metropolitan Borough of Wirral, Sheffield
2015-11-02
Active, closed
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
NCT02477696Chronic Lymphocytic Leukemia
Acerta Pharma BV
Phase 3
533
Birmingham, Bournemouth, Cambridge, Cardiff, Greater London, Hull, Leeds, Leicester
2015-07-28
Active, closed
Micra Transcatheter Pacing System Post-Approval Registry
NCT02536118Bradycardia
Medtronic
Observational
3,100
Birmingham, Bristol, Leeds, Leicester, Liverpool, London, Manchester, Middlesbrough
2015-07
Rows per page Showing 201–300 of 317
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-uk/city/leeds?page=3

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.